T-Cell-Replete Versus ex vivo T-Cell-Depleted Haploidentical Haematopoietic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukaemia and Other Haematological Malignancies

Kleinschmidt, Katharina; Lv, Meng; Yanir, Asaf; Palma, Julia; Lang, Peter; Eyrich, Matthias

doi:10.3389/fped.2021.794541

Cited by 11 publications

(8 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alpha/beta T-cell depletion was first applied in children [5]. Indeed, a review summarizing studies in children concluded that there is no clear difference in survival between PTCy and Tcell depletion in haploidentical transplants due to heterogeneity in trials, including patient populations, methodologies and supportive care approaches [13]. In our study in adult patients, we could not detect any significant difference in overall or relapse-free survival between the PTCy and T-cell depletion groups.…”

Section: Resultscontrasting

confidence: 77%

Comparison of alpha/beta T cell depletion with posttransplant cyclophosphamide in haploidentical transplantation

Ozen¹,

Gündüz²,

Aksoyoglu³

et al. 2023

j-ebr

View full text Add to dashboard Cite

To compare alpha/beta T-cell depletion with posttransplant Cyclophosphamide (PTCy) in haploidentical allogeneic transplantation in adult hematological patients, this is the first study. Method: In our study, we reported 36 haploidentical allogeneic stem cell transplants which were performed in our clinic. Results: Twenty-six of these haploidentical transplants received standard treatment and transplanted either with PTCy (n=21, 81%) or with alpha/beta T-cell depletion (n=5, 19%). Less CD34+ stem cells were administered in the T-cell depletion group. When the two groups were compared in terms of survival, no difference was found in relapse-free and overall survival in each group. Acute GVHD cases developed in the PTCy group mostly developed after CMV infection, whereas acute GVHD did not develop in the T-cell depletion group. In the PTCy group, 8 cases developed graft failure and relapse; 4 cases developed graft failure or relapse in the T-cell depletion group, and 2 of them developed graft failure or relapse following EBV infection and 1 of them following CMV infection. Conclusion:We have a small number of patients in the T cell depletion group. Due to our long follow-up period, we believe that our patients with T cell depletion can be compared with those who underwent PTCy, and similar survival results can be achieved in adult patients having hematologic malignancies.

show abstract

Section: Resultscontrasting

confidence: 77%

Comparison of alpha/beta T cell depletion with posttransplant cyclophosphamide in haploidentical transplantation

Ozen¹,

Gündüz²,

Aksoyoglu³

et al. 2023

j-ebr

View full text Add to dashboard Cite

show abstract

“…techniques using microbeads conjugated magnetically with monoclonal antibodies, 33 which allows a highly efficient negative selection of alloreactive T-cells similar to TCRαβ+ T-cells depletion, represents a valuable step forward in ex vivo graft manipulation. 34,35 These appoaches guarantee a low risk of GvHD while promoting engraftment, effective infections management and, in leukemia patients, relapse prevention 36,37 by the persistence in the graft of several cell types like Natural Killer Cells (NK-cells) and TCRγδ+ T cells. 38 Similarly, the introduction of PTCy in T-repleted haplo-SCT contributed to the reduced risk of GvHD due to the killing of emerging alloreactive T-cells in the first days after transplant, 39,40 preserving engraftment and immune reconstitution.…”

Section: Discussionmentioning

confidence: 99%

HLA‐haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties

Giardino,

Eikema,

Piepenbroek

et al. 2024

American J Hematol

Self Cite

View full text Add to dashboard Cite

Haploidentical stem cell transplantation (haplo‐SCT) represents the main alternative for children with inherited bone marrow failure syndrome (I‐BMF) lacking a matched donor. This retrospective study, conducted on behalf of the EBMT SAAWP and PDWP, aims to report the current outcomes of haplo‐SCT in I‐BMFs, comparing the different in vivo and ex vivo T‐cell depletion approaches. One hundred and sixty‐two I‐BMF patients who underwent haplo‐SCT (median age 7.4 years) have been registered. Fanconi Anemia was the most represented diagnosis (70.1%). Based on different T‐cell depletion (TCD) approaches, four categories were identified: (1) TCRαβ+/CD19+‐depletion (43.8%); (2) T‐repleted with post‐transplant Cyclophosphamide (PTCy, 34.0%); (3) In‐vivo T‐depletion with ATG/alemtuzumab (14.8%); (4) CD34+ positive selection (7.4%). The cumulative incidences (CI) of neutrophil and platelet engraftment were 84% and 76% respectively, while that of primary and secondary graft failure was 10% and 8% respectively. The 100‐day CI of acute GvHD grade III‐IV(95% CI) was 13%, while the 24‐month CI of extensive chronic GvHD was 4%. After a median follow‐up of 43.4 months, the 2‐year overall survival(OS) and GvHD/Rejection‐free Survival (GRFS) probabilities are 67% and 53%, respectively. The TCR CD3+αβ+/CD19+ depletion group showed a significantly lower incidence of both acute and chronic GvHD and higher OS (79%; p0.013) and GRFS (71%; p < .001), while no significant differences in outcomes have been observed by different diagnosis and conditioning regimens. This large retrospective study supports the safety and feasibility of haplo‐SCT in I‐BMF patients. TCRαβ+/CD19+ depletion offers higher chances of patients' survival, with a significantly lower risk of severe a‐ and c‐GvHD in I‐BMFs compared to other platforms.

show abstract

“…Haplo-HSCT using T-cell replete grafts constitutes an interesting approach, however, it has to be determined if the use T-cell-repleted grafts results in a stronger GvT-effect. So far none of the different transplantation protocols was superior over the others regarding OS or relapse ( 44 ).…”

Section: Discussionmentioning

confidence: 99%

Haploidentical hematopoietic stem cell transplantation as individual treatment option in pediatric patients with very high-risk sarcomas

Eichholz

Döring²,

Giardino³

et al. 2023

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

BackgroundPrognosis of children with primary disseminated or metastatic relapsed sarcomas remains dismal despite intensification of conventional therapies including high-dose chemotherapy. Since haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is effective in the treatment of hematological malignancies by mediating a graft versus leukemia effect, we evaluated this approach in pediatric sarcomas as well.MethodsPatients with bone Ewing sarcoma or soft tissue sarcoma who received haplo-HSCT as part of clinical trials using CD3+ or TCRα/β+ and CD19+ depletion respectively were evaluated regarding feasibility of treatment and survival.ResultsWe identified 15 patients with primary disseminated disease and 14 with metastatic relapse who were transplanted from a haploidentical donor to improve prognosis. Three-year event-free survival (EFS) was 18,1% and predominantly determined by disease relapse. Survival depended on response to pre-transplant therapy (3y-EFS of patients in complete or very good partial response: 36,4%). However, no patient with metastatic relapse could be rescued.ConclusionHaplo-HSCT for consolidation after conventional therapy seems to be of interest for some, but not for the majority of patients with high-risk pediatric sarcomas. Evaluation of its future use as basis for subsequent humoral or cellular immunotherapies is necessary.

show abstract

T-Cell-Replete Versus ex vivo T-Cell-Depleted Haploidentical Haematopoietic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukaemia and Other Haematological Malignancies

Cited by 11 publications

References 106 publications

Comparison of alpha/beta T cell depletion with posttransplant cyclophosphamide in haploidentical transplantation

Comparison of alpha/beta T cell depletion with posttransplant cyclophosphamide in haploidentical transplantation

HLA‐haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties

Haploidentical hematopoietic stem cell transplantation as individual treatment option in pediatric patients with very high-risk sarcomas

Contact Info

Product

Resources

About